Sign In
NASDAQ:DVAX
Dynavax Technologies Corporation Stock Earnings Reports
$13.87
+0.180 (+1.31%)
At Close: Mar 14, 2025
Dynavax Technologies Earnings Calls
Q4 2024
| Release date | Feb 20, 2025 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0500 |
| Revenue estimate | 72.703M |
| Revenue actual | 72.032M |
| Revenue Surprise | -0.92% |
Q3 2024
Beat
$0.120 (9.09%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.110 |
| EPS actual | $0.120 |
| EPS Surprise | 9.09% |
| Revenue estimate | 71.713M |
| Revenue actual | 80.63M |
| Revenue Surprise | 12.43% |
Q2 2024
Beat
$0.0800 (33.33%)
| Release date | Aug 06, 2024 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0800 |
| EPS Surprise | 33.33% |
| Revenue estimate | 76.1M |
| Revenue actual | 73.795M |
| Revenue Surprise | -3.03% |
Q1 2024
Missed
-$0.0700 (-40.00%)
| Release date | May 08, 2024 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0700 |
| EPS Surprise | -40.00% |
| Revenue estimate | 54.97M |
| Revenue actual | 50.79M |
| Revenue Surprise | -7.60% |
Last 4 Quarters for Dynavax Technologies
Below you can see how DVAX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Missed
| Release date | May 08, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $11.65 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0700 |
| EPS surprise | -40.00% |
| Date | Price |
|---|---|
| May 02, 2024 | $11.72 |
| May 03, 2024 | $11.74 |
| May 06, 2024 | $11.64 |
| May 07, 2024 | $11.76 |
| May 08, 2024 | $11.65 |
| May 09, 2024 | $11.01 |
| May 10, 2024 | $10.73 |
| May 13, 2024 | $11.03 |
| May 14, 2024 | $11.00 |
| 4 days before | -0.597% |
| 4 days after | -5.58% |
| On release day | -5.49% |
| Change in period | -6.14% |
Q2 2024
Beat
| Release date | Aug 06, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $10.05 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0800 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| Jul 31, 2024 | $11.19 |
| Aug 01, 2024 | $10.91 |
| Aug 02, 2024 | $10.53 |
| Aug 05, 2024 | $10.07 |
| Aug 06, 2024 | $10.05 |
| Aug 07, 2024 | $10.75 |
| Aug 08, 2024 | $10.70 |
| Aug 09, 2024 | $11.10 |
| Aug 12, 2024 | $10.90 |
| 4 days before | -10.19% |
| 4 days after | 8.46% |
| On release day | 6.97% |
| Change in period | -2.59% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $12.02 |
| EPS estimate | $0.110 |
| EPS actual | $0.120 |
| EPS surprise | 9.09% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $11.78 |
| Nov 04, 2024 | $11.79 |
| Nov 05, 2024 | $12.01 |
| Nov 06, 2024 | $12.29 |
| Nov 07, 2024 | $12.02 |
| Nov 08, 2024 | $13.01 |
| Nov 11, 2024 | $13.66 |
| Nov 12, 2024 | $13.50 |
| Nov 13, 2024 | $13.52 |
| 4 days before | 2.04% |
| 4 days after | 12.48% |
| On release day | 8.24% |
| Change in period | 14.77% |
Q4 2024
| Release date | Feb 20, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $13.33 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0500 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $12.69 |
| Feb 14, 2025 | $12.82 |
| Feb 18, 2025 | $12.93 |
| Feb 19, 2025 | $13.09 |
| Feb 20, 2025 | $13.33 |
| Feb 21, 2025 | $13.33 |
| Feb 24, 2025 | $13.42 |
| Feb 25, 2025 | $13.41 |
| Feb 26, 2025 | $13.69 |
| 4 days before | 5.04% |
| 4 days after | 2.70% |
| On release day | 0% |
| Change in period | 7.88% |
Dynavax Technologies Earnings Call Transcript Summary of Q4 2024
HEPLISAV-B Market Leader
The adult hepatitis B vaccine HEPLISAV-B captured 44% market share by the end of 2024.
Profitability
The company achieved net income of $27 million for the full year, with a fourth-quarter net income of $7 million.
Cash Position
Dynavax exited 2024 with $714 million in cash and marketable securities.
2025 Guidance
- Revenue Expectations: For 2025, Dynavax expects HEPLISAV-B net product sales to be between $305 million and $325 million, representing approximately 17% growth year-over-year.
- Adjusted EBITDA: The company anticipates adjusting EBITDA of at least $75 million.
- R&D and SG&A Expenses:
- R&D expenses are projected to increase by high teens percentage.
- SG&A expenses are expected to be roughly flat.
Growth Drivers for HEPLISAV-B
- Medicare Accessibility: From January 2025, Medicare patients gained access to hepatitis B vaccines at retail pharmacies, which is anticipated to enhance HEPLISAV-B's market share.
- HEDIS Measure Inclusion: Adult hepatitis B vaccinations being included in the Healthcare Effectiveness Data and Information Set (HEDIS) is expected to improve focus on hepatitis B vaccination in integrated delivery networks (IDNs).
Clinical Development Updates
- Shingles Vaccine Program (Z-1018):
- The company has seen promising results from a Phase I study compared to Shingrix with plans to report top-line results from an ongoing Phase I/II trial in Q3 2025.
- Future studies will aim to demonstrate differentiating factors such as improved tolerability, comparable CD4 T cell responses, and robust durability of immune responses.
- Pneumonic Plague Vaccine: A $30 million collaboration with the Department of Defense to support clinical and manufacturing activities, with a Phase II trial expected to initiate in 2025.
Share Repurchase Program
- Capital Return Strategy: Dynavax has initiated a $200 million share buyback program and completed the first $100 million in accelerated purchases with plans to finish the remaining amount by the end of 2025. The company will evaluate further buyback opportunities as needed.
Investor Confidence
Leadership expressed optimism about achieving milestones in existing pipelines and maintaining robust financial health, positioning Dynavax for future growth.
Conclusion
Management emphasized collective confidence in Dynavax's strategic approach to drive revenue growth through HEPLISAV-B and the successful advance of their clinical pipeline, including future opportunities for business development to augment growth.
Dynavax Technologies Earnings History
Earnings Calendar
FAQ
When is the earnings report for DVAX?
Dynavax Technologies Corporation (DVAX) has scheduled its earnings report for May 14, 2025 after the markets close.
What is the DVAX price-to-earnings (P/E) ratio?
DVAX P/E ratio as of Mar 14, 2025 (TTM) is 64.99.
What is the DVAX EPS forecast?
The forecasted EPS (Earnings Per Share) for Dynavax Technologies Corporation (DVAX) for the first fiscal quarter 2025 is $0.0300.
What are Dynavax Technologies Corporation's retained earnings?
On its balance sheet, Dynavax Technologies Corporation reported retained earnings of $72.03 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
